Posts filtered by tags: mRNA[x]


 

The world will have to live with COVID forever - Moderna CEO

Echoing comments from some other public health officials, Moderna (NASDAQ:MRNA) CEO Stephane Bancel said COVID-19 is likely to become an...
Tags: mRNA, Stéphane Bancel, COVID


The COVID vaccine was developed in record time thanks to mRNA. Pfizer's CEO says the technology should now be used on other viral diseases like the flu.

The Pfizer Covid-19 vaccine. Dado Ruvic/Reuters Dado Ruvic/Reuters Covid-19 vaccine forwarded vaccine science years, Pfizer's CEO said, and now it's time to use advances for other viral diseases, such as the flu. "We'll be able to provide medical solutions for other devastating diseases," the CEO said. The Pfizer BioNTech vaccine used a new method with messenger RNA to initiate the immune response. Moderna's vaccine also used mRNA. Visit Business Insider's homepage for more stories. The Co...
Tags: News, Trends, Healthcare, Fda, Pfizer, Vaccine, Flu Vaccine, Jpmorgan, Moderna, mRNA, Albert Bourla, Bourla, Burla, Ugur Sahin, Natasha Dailey, Reuters Dado Ruvic Reuters Covid


11 Questions to Ask About COVID-19 Research

Debates have raged on social media, around dinner tables, on TV, and in Congress about the science of COVID-19. Is it really worse than the flu? How necessary are lockdowns? Do masks work to prevent infection? What kinds of masks work best? Is the new vaccine safe? You might see friends, relatives, and coworkers offer competing answers, often brandishing studies or citing individual doctors and scientists to support their positions. With so much disagreement—and with such high stakes—how can we...
Tags: Parenting, Congress, Cdc, White House, Sutter Health, United States, World Health Organization, Denmark, Fox News, Fda, UC Berkeley, Coca Cola, Bell, Trump, UCSF, Oakland California


Pandemic: Wisc. pharmacist tried to ruin vaccine intentionally

By Todd Richmond | Associated Press MADISON, Wis. — A Wisconsin pharmacist convinced the world was “crashing down” told police he tried to ruin hundreds of doses of coronavirus vaccine because he believed the shots would mutate people’s DNA, according to court documents released Monday. Police in Grafton, about 20 miles north of Milwaukee, arrested Advocate Aurora Health pharmacist Steven Brandenburg last week following an investigation into the 57 spoiled vials of the Moderna vaccine, which off...
Tags: Politics, UK, Crime, News, Minneapolis, Milwaukee, Sport, Soccer, Wisconsin, Courts, Associated Press, Pfizer, Johnson, Bay Area, Aurora, Brandenburg


Can mRNA Biotechnology be Adapted to Improve Flu Vaccines and Fight Cancer?

Reuters notes the "miraculous speed" of mRNA vaccines, while also calling it "a glimpse of what's possible if it can be applied post-pandemic to treat cancer or rare diseases." The vaccine market alone is worth about $35 billion each year, and investors apparently believe mRNA companies will capture around two-third of that, leading market researcher Bernstein to evalaute the combined worth of mRNA companies at nearly $180 billion. The technology is the closest thing yet to making medicine d...
Tags: Tech, Reuters, Bernstein, Moderna, mRNA


Ten Questions to Ask About COVID-19 Research

Debates have raged on social media, around dinner tables, on TV, and in Congress about the science of COVID-19. Is it really worse than the flu? How necessary are lockdowns? Do masks work to prevent infection? What kinds of masks work best? Is the new vaccine safe? You might see friends, relatives, and coworkers offer competing answers, often brandishing studies or citing individual doctors and scientists to support their positions. With so much disagreement—and with such high stakes—how can we...
Tags: Parenting, Congress, Cdc, White House, Sutter Health, United States, World Health Organization, Denmark, Fox News, Fda, UC Berkeley, Coca Cola, Bell, Trump, UCSF, Oakland California


BioNTech scientist Katalin Karikó risked her career to develop mRNA vaccines. Americans will start getting her coronavirus shot on Monday.

Karikó and her husband celebrate their daughter's Olympic win in 2012. Katalin Karikó Scientist Katalin Karikó struggled for years to convince colleagues that messenger RNA could have disease-fighting applications in humans. In 2005, she found a way to configure mRNA so that it slipped past the body's natural defenses — a discovery that paved for the way for the world's first mRNA vaccines. The COVID-19 vaccines from both Pfizer-BioNTech and Moderna rely on this technology. Pfizer's va...
Tags: UK, Science, London, News, Germany, US, Trends, Hungary, Astrazeneca, Philadelphia, University of Pennsylvania, Pfizer, University Of Wisconsin, Massachusetts Institute Of Technology, Susan, Harvard Medical School


Scientist Katalin Karikó risked her career in pursuit of mRNA vaccines. Her achievement could rescue the world from the pandemic.

Karikó and her husband celebrate their daughter's Olympic win in 2012. Katalin Karikó Scientist Katalin Karikó struggled for years to convince colleagues that messenger RNA could have disease-fighting applications in humans. In 2005, she found a way to configure mRNA so that it slipped past the body's natural defenses — a discovery that paved for the way for the world's first mRNA vaccines. The COVID-19 vaccines from both Pfizer-BioNTech and Moderna rely on this technology. The Pfizer ...
Tags: UK, Science, London, News, Germany, US, Trends, Hungary, Astrazeneca, Philadelphia, University of Pennsylvania, Pfizer, University Of Wisconsin, Massachusetts Institute Of Technology, Susan, Harvard Medical School


Moderna COVID Vaccine is 94.5% Effective

Moderna, Inc. (Nasdaq: MRNA) reported the results of its Phase 3 study of mRNA-1273 has met the statistical criteria pre-specified in the study protocol for efficacy, with a vaccine efficacy of... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Tags: Innovation, mRNA, Moderna Inc


Moderna INC (MRNA) Q3 2020 Earnings Call Transcript

MRNA earnings call for the period ending September 30, 2020.
Tags: mRNA, Moderna INC MRNA


Combined Therapeutics Wins $250,000 MilliporeSigma Advance Biotech Grant

MilliporeSigma has awarded MIT spin-out Combined Therapeutics a check for $250,000 as the winner of its 2020 Advance Biotech Grant.Combined Therapeutics (CTx) is an early stage startup developing the second generation of therapeutic and intelligent messenger RNA (mRNA). The pre-clinical biotech aims to develop therapies to treat and prevent liver cancer using its mRNA delivery and modulation platform.The firm—founded by MIT professors Robert Langer and Dan Anderson, along with entrepreneur Roma...
Tags: Startups, Funding, Trends, Mit, National, Biotech, Financing, Life Sciences, Dan Anderson, Robert Langer, National blog main, mRNA, National Events, Xconomy Awards, MilliporeSigma, Bioprocess


Combined Therapeutics Inc Wins $250,000 MilliporeSigma Advance Biotech Grant

MilliporeSigma has awarded MIT spin-out Combined Therapeutics Inc. as the winner of its 2020 North America Advance Biotech Grant.Combined Therapeutics Inc. (CTx) is an early stage start-up developing the second generation of therapeutic and intelligent messenger RNA (mRNA). The pre-clinical biotech aims to develop therapies to treat and prevent liver cancer using its mRNA delivery and modulation platform.The firm—founded by MIT professors Robert Langer and Dan Anderson, along with entrepreneur ...
Tags: Startups, Funding, Trends, Mit, National, Biotech, Financing, Life Sciences, Dan Anderson, Robert Langer, Therapeutics Inc, National blog main, mRNA, National Events, Xconomy Awards, MilliporeSigma


Here are the 94 companies from Y Combinator’s Summer 2020 Demo Day 2

And we’re back! Today was part two of Y Combinator’s absolutely massive Demo Day(s) event for its Summer 2020 class. As we outlined yesterday, this is the first YC accelerator class to take place entirely online, from the day zero interviews all the way on through to their eventual demo day debut. We talked with YC President Geoff Ralston about what it was like to take the program fully remote (and whether or not it’ll be staying remote for the long run) . Nearly 100 companies presented yest...
Tags: Google, Amazon, TC, Y Combinator, UK, India, Africa, US, San Francisco, Tech, Merck, Nasa, Mit, Netflix, United States, Pakistan


1 Reason to Sell Moderna Now

There are multiple bear arguments floating around as reasons to sell Moderna (NASDAQ: MRNA), one of the drugmakers leading the way to develop a coronavirus vaccine. Moderna lost a petition trying to invalidate patents held by Arbutus Biopharma (NASDAQ: ABUS): The patents are unlikely to keep Moderna's coronavirus vaccine, mRNA-1273, off the market. The biggest impact would be Moderna having to pay royalties to Arbutus on sales of mRNA-1273.
Tags: Business, News, Moderna, mRNA, Arbutus Biopharma, Moderna NASDAQ


Bio Roundup: Race and Pharma, ASCO Recap, Warp Speed Ahead & More

Race is not a topic that often comes up in pharmaceutical discussions but perhaps it should. Disease doesn’t discriminate by race, but health and economic disparities put some groups at higher risk than others. And yet clinical trials fail to reflect the broad spectrum of patients that drug makers aim to treat.Racial disparities are evident in the COVID-19 pandemic, which is hitting the African American community hardest. Inequality has been thrust front and center following the death of George...
Tags: Deals, Startups, Cancer, Trends, Investing, Merck, Prostate Cancer, Multiple Sclerosis, Alzheimer's Disease, National, Epilepsy, Pfizer, Vaccine, Abbvie, Biotech, Novo Nordisk


MRNA Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Announces Moderna, Inc. Investigation and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 24, 2020 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") ...
Tags: Business, New York, News, Moderna, mRNA, Moderna Inc, Bronstein Gewirtz, Bronstein Gewirtz Grossman, Grossman LLC Announces Moderna Inc


The untold story of Moderna as the biotech's coronavirus vaccine faces a test that could make it one of the most consequential startups of all time (MRNA)

The biotech Moderna has skyrocketed to global prominence, leading the world's race for a coronavirus vaccine. The Cambridge, Massachusetts-based biotech was founded in 2010 with the ambitious goal to develop a new type of medicine. While its platform remains unproven, it is now being tested under the brightest possible spotlight of a pandemic.  Here's the inside story of Moderna's rise, from an offshoot of stem cell research to routinely shattering funding records on its way to biotech's top r...
Tags: Google, Amazon, Microsoft, Navy, California, Washington Post, France, China, US, Trends, Merck, Mit, Harvard, Cambridge, Astrazeneca, Fidelity


Bio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More

As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything resembling a pre-pandemic normal without a COVID-19 vaccine.Moderna (NASDAQ: MRNA) moved one step closer to filling that need with the release of preliminary Phase 1 data for its messenger RNA vaccine candidate. No major safety problems were reported and there were some indications that the injec...
Tags: Deals, Startups, Trends, Investing, Merck, Prostate Cancer, European Commission, Astrazeneca, National, GlaxoSmithKline, Parkinson's Disease, Biotech, Vaccines, Galapagos, Life Sciences, Roche


Dollar loses out on growing optimism about virus vaccine

Wall Street shares, emerging market assets, and commodities all rallied after encouraging data from a COVID-19 vaccine trial by U.S. drugmaker Moderna added to the optimism as more governments scale back lockdown restrictions. The euro's rally overnight came after France and Germany proposed that the European Commission borrow money on behalf of the whole EU for the recovery fund. While coronavirus infection rates in many places have now fallen to levels low enough to allow factories and...
Tags: Business, News, France, Wall Street, Germany, Eu, European Commission, Moderna, mRNA


Moderna Has Positive Phase 1 Vaccine Results and Hopes for July Phase 3 Start

Moderna (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
Tags: Innovation, mRNA


Biotech Roundup: GSK’s Ante, Shakeup at Sage, Telehealth’s Rise & More

The COVID-19 pandemic has stopped enrollment in many clinical trials and postponed the start of others but there is still life in the life sciences sector. The coronavirus research is expected. It’s the other activity that might come as a surprise.Two biotech companies have gone public in the past week; each upsized its offering and saw a healthy IPO pop. Startups are raising money, and there is more financing on the way as investment firms close new funds. Time will tell if this activity will ...
Tags: Deals, Startups, Ipo, Cancer, Time, Trends, Investing, It, Software, Anemia, European Commission, National, Epilepsy, GlaxoSmithKline, Pfizer, Vaccine


'Crazy hours, short nights': The inside story of how a buzzy biotech upstart developed a potential coronavirus vaccine in record time (MRNA)

The $10 billion biotech Moderna developed a potential coronavirus vaccine in record time, zooming past Big Pharma competitors. The company's CEO Stephane Bancel sat down with Business Insider to discuss the technology platform that drove its speed, and how the company hopes to pioneer a new way of developing vaccines.  "The speed is one dimension, but the piece that excites me the most about this technology is we can do vaccines that cannot be done using traditional technology," Bancel said. T...
Tags: Amazon, Washington, France, China, Ipo, Massachusetts, US, Trends, Shanghai, Cambridge, Fda, Norwood, Anthony Fauci, Nih, Wall Street Journal, Polaroid


Buzzy biotech Moderna is 'looking at all options' to ramp up production just days after shipping the first potential coronavirus vaccine (MRNA)

A startup biotech is leading the race to develop a coronavirus vaccine, as the scientific community and drug industry scramble to identify treatments to halt the outbreak. On Tuesday, Moderna shipped the first batches of its experimental vaccine to the National Institutes of Health. US health officials will lead the first clinical trial, planning to test the vaccine for safety in healthy adults. While the NIH prepares to start that study, Moderna executives said they are "looking at all option...
Tags: US, Trends, CMO, Bill Gates, Nih, Wuhan, Zika, Johnson Johnson, National Institutes of Health NIH, Sanofi, Cambridge Massachusetts, Moderna, mRNA, Stéphane Bancel, National Institutes of Health US


Flagship adds four exec partners to team

Flagship Pioneering has made four executive partners. They are Dr. Robert Berendes, Ron Hovsepian, Theo Melas Kyriazi and Dr. John Mendlein. PRESS RELEASE Cambridge, Mass., – Flagship Pioneering, a unique life sciences innovation enterprise, today announced the expansion of its executive partner team with new leaders dedicated to its growth-stage companies. The announcement follows Flagship’s closing of a $824 million capital pool to support the growth of human health and sustainability companie...
Tags: Trends, People, Harvard University, Ibm, John, Ruby, Syngenta, Flagship, Cfo, Boston College, McKinsey Company, Thermo Fisher Scientific, Theo, University of California Los Angeles, University of Cologne, Cambridge Mass


Hot startups like Hims and Roman are marketing Viagra to young men online, but their approach raises 2 big questions

New telemedicine companies like Hims and Roman have sprung up, offering online prescriptions for Viagra and other erectile dysfunction medications.  That erectile dysfunction can be a sign of other, more worrying health problems, particularly in younger men, is well-established among physicians.  One doctor worries about losing the "window of opportunity" to tackle health problems like heart conditions if men are getting care online rather than in a doctor's office.  Roman's CEO, a Hims medica...
Tags: Trends, Pfizer, North America, Columbia, Business Insider, Roman, PLOS Medicine, Stahl, Sexual Medicine Society, AUA, Meg Tirrell, mRNA, Peter Stahl, Reitano, American Urological Association, Lemonaid Health


VC-backed Moderna Therapeutics goes public

Cambridge, Massachusetts-based Moderna Therapeutics, a developer of messenger RNA therapeutics and vaccines, has raised $604.3 million for its IPO after pricing its over 26.2 million shares at $23 per share. The stock began trading December 7, 2018 on the NASDAQ under the ticker symbol “MRNA.” Morgan Stanley, Goldman Sachs and J.P. Morgan are the lead underwriters. Moderna’s pre-IPO backers include Sequoia Capital China, Fidelity Management & Research Company, Pictet, Viking Global Investors, Ar...
Tags: Ipo, Trends, IPOs, Healthcare, Securities And Exchange Commission, J P Morgan, Cambridge Massachusetts, Alexandria Venture Investments, Moderna Therapeutics, Morgan Securities LLC, Piper Jaffray Co, Morgan Stanley Co LLC, Broadridge Financial Solutions, Moderna, mRNA, West Street New York New York


Moderna Raises $604M and Nails Down Biotech’s Biggest IPO Ever

One of the biggest gambles in the history of the life sciences industry made it to Wall Street this evening when Moderna, a developer of messenger RNA drugs—an unproven technology with enormous potential—priced the largest biotech IPO ever.Now, finally under the scrutiny of investors and analysts, Moderna must prove that its technology has enough substance to match the hype.Cambridge, MA-based Moderna raised $604.3 million in a record biotech IPO on Thursday, selling more than 26 million shares...
Tags: Deals, Startups, Wall Street, Ipo, Boston, Trends, IPOs, Vc, Astrazeneca, Vaccines, Life Sciences, Celgene, Amgen, Gilead Sciences, Renaissance Capital, Biogen


Biotech company Moderna expects to raise up to $521.7 million in IPO: Reuters

Biotech company Moderna Inc said on Wednesday it expected to raise up to $521.7 million in its initial public offering, valuing the company at about $7.8 billion at the top end of the pricing range. The company expects its offering of 21.7 million shares to be priced between $22 and $24 per share, Moderna said in a filing (bit.ly/2FLA1dW). The company, which develops drugs based on molecules known as messenger RNAs, said it intends to use a major portion of the net proceeds on drug discovery and...
Tags: Trends, IPOs, Healthcare, Reuters, Cambridge Massachusetts, Morgan Securities LLC, Moderna, mRNA, Moderna Inc, Morgan Stanley Co LLC Goldman Sachs Co LLC


With BioNTech Deal, Pfizer Becomes Latest to Bet on mRNA Vaccines

Pfizer has become the latest drug maker to bet that synthetic messenger RNA molecules (mRNA) can be a new source for vaccines.This morning, the New York pharma company cut a deal with BioNTech, of Germany, to co-develop mRNA vaccines for flu prevention.BioNTech will run the initial human tests on these treatments, then hand the programs off to Pfizer (NYSE: PFE) for further development.Through an unspecified upfront cash payout, equity, and research payments, BioNTech could net a total of $120 ...
Tags: Deals, New York, Germany, Trends, Infectious Diseases, Flu, Pfizer, Vaccines, Life Sciences, Zika, Genentech, Sanofi, Chikungunya, Boehringer Ingelheim, Eli Lilly, Moderna Therapeutics


With $45M Translate Bio Deal, Sanofi Bets Again on mRNA Vaccines

It hasn’t been proven yet that synthetic messenger RNA molecules (mRNA) can be effective medicines. But their promise as a source for new vaccines, primarily for cancer, has enticed multiple pharmaceutical companies. The latest evidence comes from Sanofi, which just cut its second mRNA vaccine deal to date, this time with Translate Bio. Sanofi Pasteur, the vaccines division of French pharma giant Sanofi, will pay Translate—a Lexington, MA, company formerly known as RaNA Therapeutics— for...
Tags: Deals, Boston, Trends, Infectious Diseases, Vaccines, Life Sciences, Sanofi, Lexington, Boehringer Ingelheim, Eli Lilly, CureVac, Moderna Therapeutics, National blog main, New York blog main, New York top stories, Boston blog main